Search Medical Condition
Please enter condition
Please choose location from dropdown

Hokkaido Region, Japan Clinical Trials

A listing of Hokkaido Region, Japan clinical trials actively recruiting patients volunteers.

RESULTS

Found (202) clinical trials

Efficacy and Safety of MT-5199 in Subjects With Tardive Dyskinesia

The purpose of this study is to evaluate the efficacy and safety of MT-5199 administered once daily for the treatment of Tardive Dyskinesia (TD) symptoms.

Phase

0.0 miles

Learn More »

Study of OPA-15406 Ointment in Patients With Atopic Dermatitis

The purpose of this study is to assess the efficacy and safety of OPA-15406 ointment in patients with atopic dermatitis.

Phase

0.0 miles

Learn More »

S-CEI of Nexium in Paediatric Patients

The objective of this investigation is to capture the followings when Nexium capsules or Nexium granules for suspension (single-dose package) are administered to pediatric patients in clinical practice after launch. Development of adverse reactions which are unexpected from Precaution for Use Development of adverse reactions Efficacy

Phase N/A

0.0 miles

Learn More »

FASENRA SCEI for Long-term Use

The purpose of the investigation is to confirm the followings under the post-marketing actual long-term use of FASENRA Subcutaneous Injection 30 mg Syringe. Detection of unexpected Adverse Drug Reactions To grasp development of Adverse Drug Reactions To grasp contributing factors possibly having an impact on the safety and efficacy Development ...

Phase N/A

0.0 miles

Learn More »

Lynparza Breast Cancer Clinical Experience Investigation

To characterise the development of adverse drug reactions (ADRs) of bone marrow depression in patients with unresectable or recurrent BRCA mutated HER2 negative breast cancer who have previously received anticancer chemotherapy under actual post-marketing use.

Phase N/A

0.0 miles

Learn More »

Study of an Anti-OX40 Monoclonal Antibody (KHK4083) in Subjects With Moderate to Severe Atopic Dermatitis

A Phase 2, multicenter, randomized, placebo-controlled, double-blind, parallel-group study for subjects with moderate to severe AD whose disease cannot be adequately controlled with topical medications or for whom topical treatment is medically inadvisable.

Phase

0.0 miles

Learn More »

IMFINZI Specific-Clinical Experience Investigation in Patients With NSCLC After Definitive Chemoradiation Therapy

To investigate the impact of presence/absence or grade of radiation pneumonitis before starting IMFINZI, on the onset of interstitial lung disease (including radiation pneumonitis) after starting IMFINZI, in the real world in patients with locally advanced unresectable non-small cell lung cancer who are treated with the product as maintenance therapy ...

Phase N/A

0.0 miles

Learn More »

Assess Safety and Efficacy of Vilaprisan in Subjects With Endometriosis

The primary objective of this study is to assess the efficacy and safety of two doses of vilaprisan compared to placebo in women with symptomatic endometriosis. The secondary objective of this study is to evaluate the safety and tolerability of two different doses of vilaprisan in women with symptomatic endometriosis.

Phase

0.32 miles

Learn More »

A Study of the Bruton's Tyrosine Kinase (BTK) Inhibitor Ibrutinib in Participants With Steroid Dependent/Refractory Chronic Graft Versus Host Disease (cGVHD)

The purpose of this study is to evaluate efficacy of ibrutinib in Japanese participants with steroid dependent/refractory chronic graft versus host disease (cGVHD) by measuring overall cGVHD response (complete response [CR] and partial response [PR] defined by National Institutes of Health [NIH] consensus development project criteria [2014]).

Phase

0.38 miles

Learn More »

A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus

This study evaluates the efficacy, safety, and tolerability of ustekinumab in participants with active SLE according to Systemic Lupus International Collaborating Clinics (SLICC) criteria Systemic Lupus Erythematosus Disease Activity Index 2000 (SLEDAI-2K) score greater than (>=) 6, despite receiving one or more standard-of-care treatments (example, immunomodulators, antimalarial drugs, and/or glucocorticoids). ...

Phase

0.38 miles

Learn More »